Steve Bryson, PhD, science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

August 13, 2020 News by Steve Bryson, PhD

Sickle Cell Oral Treatment Xromi Approved in Scotland for Ages 2–9

The Scottish Medicines Consortium (SMC) has approved the use of Xromi (hydroxycarbamide), a liquid form of hydroxyurea, for treating children with sickle cell disease (SCD). Xromi is expected to be used in children older than 2 and younger than 9 who…

February 13, 2020 News by Steve Bryson, PhD

Pediatric SCD Patients with Acute Kidney Injury Face More Hospital Care, Higher Costs, Large–scale Analysis Finds

Pediatric patients with sickle cell disease complicated by acute kidney injury (AKI) were more likely to be admitted to the intensive care unit (ICU), had longer hospital stays, accumulated greater hospitalization costs, and had a higher rate of readmission, a large-scale analysis…

Subscribe to our newsletter

Get regular updates to your inbox.

Steve Bryson, PhD, science writer—

Articles by Steve Bryson

Sickle Cell Oral Treatment Xromi Approved in Scotland for Ages 2–9

Pediatric SCD Patients with Acute Kidney Injury Face More Hospital Care, Higher Costs, Large–scale Analysis Finds

Recent Posts

Subscribe to our newsletter